Sab Biotherapeutics Inc (SABS) 재무 분석
*모든 숫자는 백만 단위입니다.
| 기간 종료일 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|---|
| 기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
10.79%25.90 | 23.38 | 20.00 | 15.77 | 12.68 | |
| Research and Development | 11.78%18.08 | 16.17 | 13.40 | 10.73 | 8.97 |
| Operating Income/Loss | 10.79%-25.90 | -23.38 | -20.00 | -15.77 | -12.68 |
| Net Interest Income/Expense | 1.61 | - | - | - | - |
| Nonoperating Income/Loss | 306.21%3.60 | 0.89 | 1.13 | -1.09 | 58.12 |
0.85%-22.30 | -22.49 | -18.87 | -16.86 | 45.45 | |
| Attributable To Parent | 0.85%-22.30 | -22.49 | -18.87 | -16.86 | 45.45 |
| Available To Common Stockholders, Basic | 0.85%-22.30 | -22.49 | -18.87 | -2.85 | 5.34 |
| Basic Average Shares | 16.91%93.24 | 79.75 | 53.56 | 9.56 | 10.66 |
| Diluted Average Shares | 16.91%93.24 | 79.75 | 53.56 | 31.04 | 77.86 |
| Basic Earnings Per Share | 14.29%-0.24 | -0.28 | -0.35 | -0.51 | 0.50 |
| Diluted Earnings Per Share | 14.29%-0.24 | -0.28 | -0.35 | -0.46 | -0.21 |
| Undistributed Earnings/Loss Allocated To Participating Securities, Basic | - | - | - | -14.02 | 40.11 |